Skip to Content
Last Updated: 05/26/2017

2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

Several DCTD staff members will present information at the ASCO Annual Meeting External Link in Chicago, IL from June 2-6, 2017 via the following three presentation categories:

Oral Presentations

Time Title Presenter Location
Friday, June 2
1:00 PM - 1:20 PM The State of the Art in High-Grade Serous Ovarian Cancer: Update on high-grade serous ovarian carcinoma External Link Elise Kohn, MD, Cancer Therapy Evaluation Program S406
1:40 PM - 2:00 PM The State of the Art in High-Grade Serous Ovarian Cancer: Creating synthetic lethality External Link Percy Ivy, MD,
Cancer Therapy Evaluation Program
S406

Poster Presentations

Time Title Presenter Location
Saturday, June 3
1:15 PM – 4:45 PM Survival profile in breast cancer molecular subtypes without systemic and locoregional Treatment. External Link Sherry X. Yang, MD, PhD,
Developmental Therapeutics Program
Hall A; Abstract 11599;
Poster Board 299
1:15 PM – 4:45 PM Antitumor activity of indenoisoquinoline inhibitors of topoisomerase 1 (TOP1) via apoptosis and autophagocytosis pathways in animal models. External Link Robert Kinders, PhD,
Pharmacodynamic Assay Development and Implementation Section (PADIS)
Hall A; Abstract 11588;
Poster Board 288
Monday, June 5
8:00 AM - 11:30 AM A phase I trial of TRC102 (methoxyamine HCL) with temozolamide (TMZ) in patients with solid tumors and lymphomas. External Link Robert S. Meehan, MD,
Early Clinical Trials Development Program
Hall A; Abstract 2518;
Poster Board 10
8:00 AM - 11:30 AM Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas. External Link Geraldine O’Sullivan Coyne, MD, PhD, Early Clinical Trials Development Program Hall A; Abstract 2558;
Poster Board 50
8:00 AM - 11:30 AM Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors. External Link Geraldine O’Sullivan Coyne, MD, PhD, Early Clinical Trials Development Program Hall A; Abstract TPS2609;
Poster Board 94B
8:00 AM – 11:30 AM Suitability factors of core needle biopsies for pharmacodynamic (PD) studies. External Link Ralph E. Parchment, PhD, Office of the Director; Frederick National Laboratory for Cancer Research Hall A; Abstract 2540; Poster Board 32
1:15 PM - 4:45 PM National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers. External Link Andrea Denicoff, RN, MS, Cancer Therapy Evaluation Program Hall A; Abstract 6542; Poster Board 364
1:15 PM - 4:45 PM Transparency around disapproval reasons of early-phase trial proposals submitted to the National Cancer Institute (NCI). External Link Holly A. Massett, PhD, Cancer Therapy Evaluation Program Hall A; Abstract 6585;
Poster Board 407

Meet-the-Expert Presentations

NCI Exhibit Booth # 4052

Time Topic Presenter
Saturday, June 3
9:30 AM – 10:00 AM NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Alice Chen, MD,
Early Clinical Trials Development Program
10:15 AM – 10:45 AM CTCAE- Common Terminology Criteria for Adverse Events Alice Chen, MD,
Early Clinical Trials Development Program
12:30 PM – 1:00 PM Everything You Wanted to Know about the NCI-Pediatric MATCH Trial Nita Seibel, MD,
Cancer Therapy Evaluation Program
Monday, June 5
12:30 PM – 1:00 PM The NCI Formulary: A Cancer Moonshot Initiative Jason Cristofaro, JD, PhD,
Office of the Director
1:15 PM – 1:45 PM Precision Medicine in Lung Cancer Trials Shakun Malik, MD,
Cancer Therapy Evaluation Program
2:00 PM – 2:30 PM Biomarker Development in NCI Early Phase Trials Tracy Lively, PhD,
Cancer Diagnosis Program
3:30 PM – 4:00 PM Partnering with the NCI Developmental Therapeutics Program for Developing New Cancer Treatments Rose Aurigemma, PhD,
Developmental Therapeutics Program